Lenskart vs Titan EyeCare: mapping India's $9.2 billion eyewear battle post-listing
Fresh off its NSE debut at Rs 390 (down 2.23% over a month), Lenskart squares off against Titan EyeCare across seven factors. Lenskart's 500+ remote testing stores, next-day delivery in 58 cities and ~4M frames made in H1 face Titan's 871 EyeCare stores and 69.2% Q2 product margin in a market where Titan holds under 12% share.
What happened
Comparison of India's eyewear leaders Lenskart and Titan EyeCare post Lenskart's NSE listing, covering share performance, market size, business models, store
Key facts
- listed at Rs 390 vs Rs 402 issue price
- Lenskart -2.23% over month
- Titan +0.99% month, +10.85% year
- $9.2 billion eyewear market
- Rs 30,000 crore market (Titan est.)
- Titan share <12%
- 9.3M eye tests H1 FY26
- 46% first-time users
- 203 net new stores, 431 cities
- 500+ remote eye testing stores
- next-day delivery in 58 cities
- 871 Titan EyeCare stores (Sep 2025)
- Q2 product margin 69.2%
- 35-40% frame cost advantage
- ~4M frames manufactured H1
Why this matters
With Titan controlling less than 12% of a $9.2B market, both players face a fragmented landscape ripe for regional chain acquisitions and supply-chain consolidation to lock in scale advantages.
What to watch
- Lenskart's first post-listing quarterly results and profitability/margin disclosure
- Titan EyeCare store count and same-store growth in next quarterly update
- Lenskart share price stabilization vs continued slide below Rs 390
- Discounting intensity and promotional cadence during festive/wedding season
- Any capital raise, M&A, or international expansion announcement from Lenskart
- Shifts in unit economics: delivery expansion cost vs order density
- Lenskart accelerates city coverage expansion (58+ cities) and store rollout using IPO proceeds
- Titan announces new EyeCare store additions beyond 871 and premium lens/frame launches
- Lenskart pushes private-label and in-house manufacturing to defend gross margin against Titan's 69.2%
- Both intensify tech differentiation: remote testing, AR try-on, subscription/insurance tie-ups
- Watch for regional player consolidation or acquisition to build scale defensively